BR112022009006A2 - Composições e métodos para recombinação de alta eficiência de moléculas de rna - Google Patents

Composições e métodos para recombinação de alta eficiência de moléculas de rna

Info

Publication number
BR112022009006A2
BR112022009006A2 BR112022009006A BR112022009006A BR112022009006A2 BR 112022009006 A2 BR112022009006 A2 BR 112022009006A2 BR 112022009006 A BR112022009006 A BR 112022009006A BR 112022009006 A BR112022009006 A BR 112022009006A BR 112022009006 A2 BR112022009006 A2 BR 112022009006A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
rna molecules
high efficiency
molecules
Prior art date
Application number
BR112022009006A
Other languages
English (en)
Inventor
Christoph BACHMANN Lukas
Lawrence PFAFF Samuel
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/025430 external-priority patent/WO2020205604A1/en
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of BR112022009006A2 publication Critical patent/BR112022009006A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Abstract

COMPOSIÇÕES E MÉTODOS PARA RECOMBINAÇÃO DE ALTA EFICIÊNCIA DE MOLÉCULAS DE RNA. A presente invenção refere-se a composições e sistemas para reconstituição de moléculas de RNA, incluindo métodos para o uso dessas moléculas. Por exemplo, essas moléculas podem ser usadas para fornecer uma sequência de codificação de proteínas sobre dois ou mais vetores virais (como AAVs), resultando na reconstituição da proteína de comprimento total em uma célula. Tais métodos podem ser usados para distribuir uma proteína terapêutica, por exemplo, para tratar uma doença genética ou câncer.
BR112022009006A 2019-11-11 2020-09-30 Composições e métodos para recombinação de alta eficiência de moléculas de rna BR112022009006A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933714P 2019-11-11 2019-11-11
PCT/US2020/025430 WO2020205604A1 (en) 2019-03-29 2020-03-27 High-efficiency reconstitution of rna molecules
PCT/US2020/053643 WO2021096605A1 (en) 2019-11-11 2020-09-30 Compositions and methods for high-efficiency recombination of rna molecules

Publications (1)

Publication Number Publication Date
BR112022009006A2 true BR112022009006A2 (pt) 2022-10-11

Family

ID=75911442

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009006A BR112022009006A2 (pt) 2019-11-11 2020-09-30 Composições e métodos para recombinação de alta eficiência de moléculas de rna

Country Status (11)

Country Link
US (1) US20220265855A1 (pt)
EP (1) EP4058571A1 (pt)
JP (1) JP2023500957A (pt)
KR (1) KR20220113940A (pt)
CN (1) CN114945666A (pt)
AU (1) AU2020384996A1 (pt)
BR (1) BR112022009006A2 (pt)
CA (1) CA3157799A1 (pt)
IL (1) IL292904A (pt)
MX (1) MX2022005670A (pt)
WO (1) WO2021096605A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110743A (en) 1995-02-10 2000-08-29 The Regents Of The University Of California Development and use of human pancreatic cell lines
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules

Also Published As

Publication number Publication date
IL292904A (en) 2022-07-01
EP4058571A1 (en) 2022-09-21
MX2022005670A (es) 2022-07-19
US20220265855A1 (en) 2022-08-25
KR20220113940A (ko) 2022-08-17
CA3157799A1 (en) 2021-05-20
JP2023500957A (ja) 2023-01-11
WO2021096605A1 (en) 2021-05-20
CN114945666A (zh) 2022-08-26
AU2020384996A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
BR112019001887A2 (pt) composições e métodos para o tratamento de doença associada a cep290
BR112016028023A2 (pt) Composições e métodos de administração de tratamentos para infecções virais latentes
MD3433368T2 (ro) Trans-replicarea ARN
MX2019000252A (es) Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112019000107A2 (pt) composições e métodos com base em crispr / cas9 para o tratamento do câncer
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
BR112018076124A2 (pt) tratamento de amd utilizando a variante de aav2 com aflibercept
BR112016009465A2 (pt) Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso
BR112016024579A2 (pt) métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva
BR112016013516A8 (pt) complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112016013547A2 (pt) Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
BR112013031262A2 (pt) "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica".
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
BR112020026125A8 (pt) Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
BRPI0710671B8 (pt) uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
BRPI0714495B8 (pt) lentivírus deficiente para replicação recombinante pseudotipado
CY1123760T1 (el) Ανασυνδυασμενοι φορεις aav που εκφραζουν οστεοπροστατευτικα γονιδια, που περιλαμβανουν has2 και λουμπρικινη, χρησιμοι στην θεραπευτικη αγωγη οστεοαρθριτιδας και συναφων παθησεων των αρθρωσεων στα θηλαστικα
BR112013021986A2 (pt) "derivados de fosforamidato de 5-fluoro-2'-desoxiuridina, seus usos e seu processo de preparação, composição farmacêutica e método para sua preparação"
MX352205B (es) Sistemas de expresion.